-
KIF5B-RET (V804L), Active
KIF5B-RET (V804L), Active
- 中文名称：
- KIF5B-RET (V804L), Active
- 英文名称：
- KIF5B-RET (V804L), Active
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA73913
- 规格：
- 0.01 mg|0.05 mg|0.5 mg|2x0.5 mg|3x0.5 mg
- 保存建议：
- Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- Recombinant protein stored in 50mM Tris-HCl, pH7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Recombinant human fusion KIF5B (1-575 a.a., exons1-15) -RET (V804L)(713 a.a. -end, exons 14-21), was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number of KIF5B is NM_004521 and RET is NM_020630.
RET or ret proto-oncogene is a member of the cadherin superfamily that encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement (1). RET signaling pathway, by regulating the development of both the nervous and lymphoid system in the gut, plays a key role in the molecular mechanisms that orchestrate intestine organogenesis (2). The KIF5B-RET fusion was reported to be one of the driver mutations of lung adenocarcinomas and that Vandetanib inhibits the anchorage-independent growth activity induced by the fusion.
